Literature DB >> 20363750

Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2.

Akiko Shimahara1, Norio Yamakawa, Ichiro Nishikata, Kazuhiro Morishita.   

Abstract

Ecotropic viral integration site 1 (EVI1) is an important transcription factor for leukemogenesis. EVI1 is a member of a group of transcription factors with C-terminal binding protein (CtBP)-binding motifs that act as transcriptional co-repressors; however, we recently found that EVI1 directly activates GATA2 transcription, which is an important gene for the maintenance of hematopoietic stem cells. We show here that EVI1-activated GATA2 transcripts derive from exon 1S of GATA2, which is specifically activated in neural and hematopoietic cells. EVI1 was acetylated by the histone acetyltransferase p300/CBP association factor (P/CAF) in myeloid leukemia cells and hematopoietic progenitor cells. Acetylation at Lys(564), which is adjacent to the CtBP-binding consensus sequence of EVI1, was found to be important for transcriptional activation of GATA2. Mutation of Lys(564) to alanine (K564A) markedly reduced the ability of EVI1 to bind DNA and activate transcription of GATA2. Furthermore, we confirmed that Lys(564) in EVI1 was specifically acetylated in leukemia and primary hematopoietic cells by using an antibody directed against an acetylated Lys(564) EVI1 peptide. Moreover, co-transfection of P/CAF with EVI1 overcame the suppressive effect of the CtBP co-repressor and resulted in GATA2 transcriptional activation; nonetheless, CtBP2 was still included in the protein complex with EVI1 and P/CAF on the EVI1-binding site in the GATA2 promoter region. Thus, acetylation of EVI1 at Lys(564) by P/CAF enhances the DNA binding capacity of EVI1 and thereby contributes to the activation of GATA2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20363750      PMCID: PMC2878005          DOI: 10.1074/jbc.M110.102046

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Identification of human GATA-2 gene distal IS exon and its expression in hematopoietic stem cell fractions.

Authors:  X Pan; N Minegishi; H Harigae; H Yamagiwa; M Minegishi; Y Akine; M Yamamoto
Journal:  J Biochem       Date:  2000-01       Impact factor: 3.387

2.  c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300.

Authors:  A Tomita; M Towatari; S Tsuzuki; F Hayakawa; H Kosugi; K Tamai; T Miyazaki; T Kinoshita; H Saito
Journal:  Oncogene       Date:  2000-01-20       Impact factor: 9.867

3.  The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion.

Authors:  J Comijn; G Berx; P Vermassen; K Verschueren; L van Grunsven; E Bruyneel; M Mareel; D Huylebroeck; F van Roy
Journal:  Mol Cell       Date:  2001-06       Impact factor: 17.970

4.  Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-mediated acetylation.

Authors:  H L Hung; A Y Kim; W Hong; C Rakowski; G A Blobel
Journal:  J Biol Chem       Date:  2001-01-11       Impact factor: 5.157

5.  A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.

Authors:  N Mochizuki; S Shimizu; T Nagasawa; H Tanaka; M Taniwaki; J Yokota; K Morishita
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

6.  Acetylation of adenovirus E1A regulates binding of the transcriptional corepressor CtBP.

Authors:  Q Zhang; H Yao; N Vo; R H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

7.  P/CAF-mediated acetylation regulates the function of the basic helix-loop-helix transcription factor TAL1/SCL.

Authors:  S Huang; Y Qiu; Y Shi; Z Xu; S J Brandt
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

8.  C-terminal-binding protein directly activates and represses Wnt transcriptional targets in Drosophila.

Authors:  Ming Fang; Jiong Li; Timothy Blauwkamp; Chandan Bhambhani; Nathan Campbell; Ken M Cadigan
Journal:  EMBO J       Date:  2006-05-18       Impact factor: 11.598

9.  Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells.

Authors:  Susumu Goyama; Go Yamamoto; Munetake Shimabe; Tomohiko Sato; Motoshi Ichikawa; Seishi Ogawa; Shigeru Chiba; Mineo Kurokawa
Journal:  Cell Stem Cell       Date:  2008-08-07       Impact factor: 24.633

10.  Acetylation at a lysine residue adjacent to the CtBP binding motif within adenovirus 12 E1A causes structural disruption and limited reduction of CtBP binding.

Authors:  David Molloy; Katie L Mapp; Rachel Webster; Phillip H Gallimore; Roger J A Grand
Journal:  Virology       Date:  2006-08-17       Impact factor: 3.616

View more
  11 in total

1.  Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.

Authors:  Emilie A Bard-Chapeau; Justin Jeyakani; Chung H Kok; Julius Muller; Belinda Q Chua; Jayantha Gunaratne; Arsen Batagov; Piroon Jenjaroenpun; Vladimir A Kuznetsov; Chia-Lin Wei; Richard J D'Andrea; Guillaume Bourque; Nancy A Jenkins; Neal G Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-19       Impact factor: 11.205

2.  Regulation of the oncoprotein KLF8 by a switch between acetylation and sumoylation.

Authors:  Alison M Urvalek; Heng Lu; Xianhui Wang; Tianshu Li; Lin Yu; Jinghua Zhu; Qishan Lin; Jihe Zhao
Journal:  Am J Transl Res       Date:  2010-11-21       Impact factor: 4.060

3.  EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.

Authors:  Emilie A Bard-Chapeau; Jayantha Gunaratne; Pankaj Kumar; Belinda Q Chua; Julius Muller; Frederic A Bard; Walter Blackstock; Neal G Copeland; Nancy A Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

4.  EVI1 acts as an inducible negative-feedback regulator of NF-κB by inhibiting p65 acetylation.

Authors:  Xiangbin Xu; Chang-Hoon Woo; Rachel R Steere; Byung Cheol Lee; Yuxian Huang; Jing Wu; Jinjiang Pang; Jae Hyang Lim; Haidong Xu; Wenhong Zhang; Anuhya S Konduru; Chen Yan; Michael T Cheeseman; Steve D M Brown; Jian-Dong Li
Journal:  J Immunol       Date:  2012-05-11       Impact factor: 5.422

5.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.

Authors:  Hiromi Yamazaki; Mikiko Suzuki; Akihito Otsuki; Ritsuko Shimizu; Emery H Bresnick; James Douglas Engel; Masayuki Yamamoto
Journal:  Cancer Cell       Date:  2014-04-03       Impact factor: 31.743

6.  The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.

Authors:  Norio Yamakawa; Kazuko Kaneda; Yusuke Saito; Emi Ichihara; Kazuhiro Morishita
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

Review 7.  Interplay between cofactors and transcription factors in hematopoiesis and hematological malignancies.

Authors:  Zi Wang; Pan Wang; Yanan Li; Hongling Peng; Yu Zhu; Narla Mohandas; Jing Liu
Journal:  Signal Transduct Target Ther       Date:  2021-01-20

Review 8.  EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.

Authors:  Christine Birdwell; Warren Fiskus; Tapan M Kadia; Courtney D DiNardo; Christopher P Mill; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2021-03-22       Impact factor: 11.037

9.  Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability.

Authors:  Daniel J White; Richard D Unwin; Eric Bindels; Andrew Pierce; Hsiang-Ying Teng; Joanne Muter; Brigit Greystoke; Tim D Somerville; John Griffiths; Simon Lovell; Tim C P Somervaille; Ruud Delwel; Anthony D Whetton; Stefan Meyer
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

10.  SUMOylation of sPRDM16 promotes the progression of acute myeloid leukemia.

Authors:  Song Dong; Jieping Chen
Journal:  BMC Cancer       Date:  2015-11-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.